Clinical Trial Detail

NCT ID NCT01026337
Title Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
Recruitment Completed
Gender both
Phase Phase 0
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

renal cell carcinoma

Therapies

Sunitinib

Age Groups: adult senior

No variant requirements are available.